Darwin Wealth Management
SMMT icon

Darwin Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Darwin Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.12K Buy
+303
New +$4.53K ﹤0.01% 761
2024
Q4 		– Sell
-1,150
Closed -$25.2K – 695
2024
Q3 		$25.2K Buy
+1,150
New +$16.1K 0.01% 290

Other funds holding SMMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Hohimer Wealth Management
Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Darwin Wealth Management's SMMT Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 303 shares worth $5.12K. The stake represents ﹤0.01% of the portfolio and ranks #761 among its holdings. This is a return to the name: Darwin Wealth Management previously reported a position in SMMT as recently as Q3 2024.

Darwin Wealth Management first reported a position in SMMT in Q3 2024 and has held it in 2 quarters since. The position peaked at $25.2K in Q3 2024. 141 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Darwin Wealth Management held 303 shares of Summit Therapeutics worth $5.12K as of Q3 2026.
  • Summit Therapeutics was a new Darwin Wealth Management position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #761 holding.
  • Darwin Wealth Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Darwin Wealth Management's Summit Therapeutics position peaked at $25.2K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.